Abstract Pancreatic dysfunction during diabetes is linked to the induction of endoplasmic reticulum (ER) stress on pancreatic beta (β) cells. Our laboratory recently discovered that p21 protects from diabetes by modifying the outcome of ER stress response. In the present study, we explored the antidiabetic activity of ciclopirox (CPX), an iron chelator and recently described activator of p21 expression. The effects of CPX in beta cell survival and function were assessed in cultured islets in vitro as well as in diabetic mice in vivo. The consequences of CPX in high glucose-induced insulin release and reactive oxygen species (ROS) production were also evaluated. Islet survival assays confirmed the significance of p21 in the regulation of glucotoxicity and suggested that CPX counteracts glucotoxicity in a manner that depends on p21. In vivo, administration of CPX in wild-type (WT) diabetic mice restored glucose homeostasis. In WT-cultured islets, CPX suppressed the expression of ER stress markers BiP, GRP94, and CHOP and reduced the levels of ROS during culture at high glucose. This reduction of ER stress may be associated with the ability of CPX to inhibit insulin release. Iron citrate stimulated insulin release, which was inhibited by CPX that functions as an iron chelator. It is conceivable that inhibition of insulin production constrains ER stress in islets promoting their survival and thus protecting from diabetes in vivo. This unfolded protein response (UPR)-antagonizing activity of CPX suggests application for the management not only of diabetes but also of other conditions related to ER stress.
Introduction
Endoplasmic reticulum (ER) stress is intrinsic to the pathogenesis of diabetes by mechanisms that involve the progressive loss of beta (β) cell mass due to the inability of β cells to cope with the increased demands for insulin production and secretion [1, 21] . Thus, alleviation of the pro-apoptotic activity of ER stress during diabetes emerges as a strategy of choice during diabetes development. We have reported that deregulation of p21 activity occurs during ER stress and is associated with the cytotoxic effects of the unfolded protein response (UPR) [14] [15] [16] . In the context of diabetes, we have found that stimulation of p53/p21 expression by nutlin-3a, a pharmacological activator of p53 stability [34] , is beneficial for diabetes in mice [15, 18] . Similar results, on the beneficial activity of nutlin-3a in diabetes, have also been reported by others [30] while the specific suppression of p21 during ER stress and its pro-survival activity during DNA damage-induced apoptosis have also been suggested [19] .
The fact that besides p21 stimulation, p53 stabilization by nutlin-3a also elicits pro-apoptotic effects that may likely compromise its beneficial activities for diabetes management suggests that bypassing this death-inducing function of p53 may bear significant antidiabetic value. Consistently with this notion, p21-deficient diabetic mice not only were not responsive to nutlin-3a but were rather more sensitive to diet-induced diabetes than their wild-type counterparts [4] . This is in line with the notion that in the absence of p21, the pro-apoptotic effects of p53 persist, reducing islets' survival and function during treatment of diabetic mice with nutlin-3a.
In the present study, we explored how ciclopirox (CPX), which stimulates p21 expression [12] , affects glucose homeostasis in diabetic mice and insulin release in cultured pancreatic islets. CPX (IUPAC name: 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; trade name: Loprox) is an iron chelator that, besides the stimulation of p21 expression, can also cause accumulation of hypoxia-inducible factor 1 (HIF-1) transcription factor in the nucleus [35] . HIF-1 is the master regulator of oxygen homeostasis that stimulates angiogenesis at conditions of limited oxygen supply, and CPX was shown to stimulate HIF-1-dependent gene expression [11, 35] . Importantly, CPX was also shown to possess antitumor activity by mechanisms that are likely p53 independent, further justifying its use as an activator of p21 expression that operates independently of p53 stabilization [17, 36] . Our results suggest that CPX possesses antidiabetic activity that is associated to its ability to modulate the intensity of ER stress.
Materials and methods

Animals and islets
C57BL/6 mice used in these studies were originally purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in our facilities. Animal care and experiments were carried out in accordance with the guidelines of the Animal Facilities by the Athens University Medical School Ethics Committee in agreement with the European Union (approval no. 7924 /12/12/2014).
Islet isolation and viability assessment
Pancreatic islets from wild type, p21 deficiency, p53 deficiency, and C/EBP homologous protein (CHOP) deficiency were manually isolated from female C57BL/6 mice by the collagenase digestion method (Sigma-Aldrich) [10] . After isolation, the islets were incubated at 37°C with 95 % air and 5 % CO 2 in an RPMI 1640 medium (Gibco, cat. no. 11879) containing 5.5 mM glucose, supplemented with 10 % FBS and 100 units/ml streptomycin/ampicilin. After culture, mouse islets were treated with dithizone (DTZ) (Merck; Whitehouse Station, NJ, USA; http://www.merck.com) for their specificity, by DTZ staining. The stock solution was prepared with 50 mg of DTZ in 5 ml of dimethyl sulfoxide (DMSO) and stored briefly at −20°C. In vitro DTZ staining was performed by adding 10 μl of the stock solution to 1 ml Krebs-Ringer bicarbonate buffer (pH 7.4) with HEPES (10 mM) (KRBH) and incubated at 37°C for 10-15 min. After the dishes were thrice rinsed with HBSS, clusters stained in crimson red were examined with a stereomicroscope. After examination, the dishes were refilled with DMEM containing 10 % FBS. After 5 h, all traces of stain had disappeared. All the islets stained with DTZ were stained by crimson red. After 5 h, all traces of stain had disappeared. Islets were then incubated with extracellular Krebs-Ringer (KR) solution (Sigma-Aldrich) for 30 min at 37°C prior to the experiment. Islet cell viability was assessed in intact islets by using the CellTiter 96 AQueous One Solution Cell Proliferation Assay from Promega (Madison, USA). The assay is based on the reduction of a tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) inner salt by metabolically active cells into a colored product and recently has been used successfully by other groups for assessment of islets' viability [29] . Mouse islets of each of the four genotypes above, of the first survival experiment, were seeded onto a 96-well plate at 50 islets per well in 100 μl of RPMI 1640 medium (Gibco, cat. no. 11879) in 5.5-, 17-, or 25-mM glucose-containing media for 24 and 48 h. For the second survival experiment, islet cells of each of the four genotypes above were incubated onto a 96-well plate at 50 islets per well in 100 μl of RPMI 1640 medium followed by increasing concentration amounts of normal (5.5 mM), high (17 mM), and very high (25 mM) glucose in the culture media for 24 h; then, they were left to recover for 48 h in normal glucose (5 mM)-containing media. After the incubation period, 10 μl of the MTS was added to each well. The microplate was incubated in a humidified atmosphere for 4 h. Then, absorbance is recorded at a wavelength of 490 nm with a 96-well plate using a Varioskan Flash microplate reader (ThermoScientific). The quantity of formazan produced is proportional to the number of living cells in culture. Each experiment was done in triplicate.
Western blotting
The mouse islets were lysed in RIPA buffer (50 mM Tris, pH 7.2; 150 mM NaCl; 1 % sodium deoxycholate; 0.1 % SDS; 1 % Triton X-100; 10 mM NaF; 1 mM Na3VO4; protease inhibitor cocktail (1:1000, Sigma, St. Louis, MO, USA)) and were subjected to immunoblot analysis by standard methods. Proteins were resolved on a 10 % SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Membranes were probed overnight with GADD153 (F-168), sc-575 antibody from Santa Cruz Biotechnology (1:50); p21 (F-5), sc-6246 antibody from Santa Cruz Biotechnology (1:200); actin, clone C4 MAB1501 antibody from Millipore (Billerica, MA, USA) (1:2000); BiP antibody (cat. no. 3183) from Cell Signaling (Danvers, MA, USA) (1:1000); GRP94 (H-212), sc-11402 antibody from Santa Cruz Biotechnology (1:500); and insulin rabbit polyclonal H-86, sc-9168 antibody from Santa Cruz Biotechnology (1:500), followed by incubation with horseradish peroxidase-conjugated (HRP) antimouse (1:10,000) and goat antirabbit IgG (1:10,000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 1 h. After incubation with enhanced chemiluminescence reagents (Santa Cruz Biotechnology, Inc.), membranes were exposed to X-ray film (Fuji, Fischer Scientific) and then were analyzed using an ImageJ software for Windows.
In vivo analysis of antidiabetic effect of CPX Mice were randomly grouped. The first group of C57BL/6 mice, 4-5 weeks old, were fed with a control chow diet containing 10 % of kilocalorie as fat (low-fat diet) OpenSource Diets (New Brunswick, NJ, USA) D12450B and drinking water with no added sucrose (control). The second group of C57BL/6 mice 4-5 weeks old were fed with a diet containing 40 % kcal as a high-fat diet (HFD; OpenSource Diets (New Brunswick, NJ, USA) D12451, with free access to (10 %) sweetened water (sucrose). Mice with a glucose concentration after 6 h of fasting exceeding 180 mg/dl were considered diabetic, after two consecutive glucose measurements. The blood glucose levels were measured using an Accu-Chek blood glucose monitor (Roche, Indianapolis, IN, USA) using blood samples collected from the tail vein. All glucose readings were performed after a 6-h fasting. Diabetic mice were treated daily by oral gavages (In this procedure, a bulb-tipped gastric gavage needle is attached to a syringe and used to deliver the compound into the stomach. After the needle is passed to the correct length, the compound may be injected.) for 20 days with CPX (25 mg/kg) prepared in a solution (4 % ethanol, 5.2 % Tween 80, and 5.2 % PEG 400) or vehicle control. The mice were then sacrificed, and the pancreata were preserved in 10 % buffered formalin for later histological examination.
Glucose level determination and intraperitoneal insulin tolerance test
Mice were fasted for 6 h. Glucose levels of mice were measured by an Accu-Chek Active meter with blood sample obtained from the tail. For glucose tolerance, mice were injected i.p. with 2 g glucose/kg and blood glucose was checked at different time points as graphically indicated (at either 0, 30, 60, 90, 120, 160, or 220 min). For insulin resistance test, mice were injected intraperitoneally at a dose of 0.75 units/kg with human insulin (0.75 U/kg body weight; Sigma) at different time points as indicated (at either 0, 30, 60, 90, 120, or 160 min), as for glucose tolerance after insulin injection, and blood glucose was measured as described above.
Islet number measurements
Pancreatic tissue samples were fixed with 10 % buffered formalin, processed by standard methods for paraffin embedding, sectioned into 4-μm tissue sections, mounted on poly-L-lysine (Sigma)-coated slides, and dried overnight at 37°C (7). Sections were then dewaxed in xylene and then rehydrated. Finally, sections were stained with hematoxylin and eosin. Islet numbers were assessed in serial sections of pancreata and expressed as the product of islet numbers and pancreatic weight.
Determination of insulin secretion
Mouse islet cells were seeded onto a 96-well plate at 50 islets per well in 100 μl of RPMI 1640 medium (Gibco, cat. no. 11879) containing 5.5 mM glucose. Islets were resuspended in extracellular KR solution (Sigma-Aldrich) for 30 min at 37°C. After washing with the above buffer, the islets were further incubated with KRBH supplemented with 5.5 or 17 or 25 mM glucose for 30 and 60 min alone or in combination with CPX (20 μμ). Released insulin in the supernatant was measured by the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc.) in accordance with the manufacturer's guidelines.
Measurement of cellular ROS production
ROS measurements were measured by using the DCFDA Cellular ROS Detection Assay Kit (Abcam/Mitosciences) in a 96-well dark microplate in accordance with the manufacturer's guidelines. Briefly, 30 islets in a 100-μl RPMI culture medium 1640 containing 5.5 mM glucose were seeded into each well. On the day of the experiment, the islets were incubated with KR buffer containing 0.01 % (w/v) bovine serum albumin (BSA), 16 mM HEPES, and 2.8 mM glucose for 30 min at 37°C. Then, the islets were incubated with KRBH supplemented with either 5.5 or 25 mM glucose alone or in combination with CPX (20 μμ) treatment for 24 h and iron citrate alone with increasing concentrations (20-200 mg/l) or in combination with CPX treatment for 24 h. The islets were washed with PBS and stained with 20-μM DCFH-DA in the dark for 30 min at 37°C. After incubation, DCFH-DA was removed, and the islets were washed with 1× buffer solution. Samples were analyzed using a Varioskan Flash microplate reader (Thermo Scientific) with an excitation wavelength at 485 nm and an emission wavelength at 535 nm. tert-Butyl hydroperoxide (TBHP) was used as positive control. The results shown reflect the average of two independent experiments, each of which was performed in triplicates.
Measurement of serum ferritin levels
Animals were anesthetized using injectable ketamine/ xylazyne. Blood samples were collected in EDTA-coated Eppendorf tubes centrifuged at 1500 rpm (453×g) for 10 min. The supernatant (serum) was carefully transferred into 0.5-ml Eppendorf tubes and stored at −80°C for further analysis. Serum ferritin levels were determined using the Ferritin (FTL) ELISA Kit (ab157713, Abcam, Cambridge, MA, USA) in accordance with the manufacturer's guidelines. The results shown reflect the average of two independent experiments, each of which was performed in triplicates.
Statistics
Statistical analysis was performed by the Student's t test. Differences were considered significant when P < 0.05. All values are expressed as average ± SD.
Results
Islets' survival during glucotoxicity in relation to p53, p21, and CHOP status Initially, we explored how p21, p53, and CHOP deficiencies affect the sensitivity of pancreatic islets to glucotoxicity. As shown in Fig. 1 , culture of wild-type (WT) pancreatic islets at increasing amounts of glucose induced toxicity by a timedependent mechanism. Consistently with the pro-apoptotic role of CHOP during ER stress, CHOP deficiency conferred resistance since only culture at high glucose for 48 h significantly inhibited islet growth (Fig. 1a) . In agreement with the protective role of p21 and p53 during the UPR, ablation of any of these cell cycle regulators sensitized islets to the cytotoxic effects of high glucose (Fig. 1a) . A trend, albeit not confirmed statistically, for more potent pro-survival activity conferred by p21 than p53, especially for 17 mM, was unveiled because for the latter, it may be masked by its concomitant pro-apoptotic activity. The contribution of each of p21, p53, and CHOP in determining glucotoxicity is shown in Fig. 1b which illustrates the relative survival of islets at 17 and 25 mM glucose in comparison with their survival at normal glucose.
CPX promotes islet survival under glucotoxic conditions
In view of the potent sensitizing activity of p21 ablation against glucotoxicity, we evaluated how pharmacological stimulation of p21 expression promotes islets' survival. To that end, we utilized CPX, a previously described stimulator of p21 expression. Specifically, islets from WT, p21-deficient, p53-deficient, and CHOP-deficient mice were exposed to CPX at 20 μμ for 24 h under increasing glucose amounts in the culture media; then, they were left to recover for 48 h in normal glucose-containing media and their survival was assessed (Fig. 2a) . The 48-h recovery in normal media was deemed necessary because CPX, by inducing p21 expression, would inflict cell cycle arrest in islets masking the effects of glucotoxicity. Indeed, CPX treatment of WT islets under normal glucose significantly inhibited islet survival. As shown in Fig. 2b , despite this cytostatic effect in WT islets under normal glucose, CPX protected WT but not p21-deficient animals from glucotoxicity, suggesting that intact p21 expression is required for the pro-survival activity of CPX. A similar trend was also found for p53, the major regulator of p21 expression. Considering though that the p21-stimulatory activity of CPX in the islets is also p53 independent, as described earlier for cancer cells [39] , this observation suggests that p53 deregulation may alleviate the pro-survival activity of CPX by alternative mechanisms. Thus, p21/p53 expression is required for CPX to produce its protective effects at glucotoxic conditions. Consistently with its pro-apoptotic role during ER stress, CHOP ablation conferred resistance of islets to glucotoxicity (Fig. 2b) .
Ciclopirox produces antidiabetic activity in WT mice
Subsequently, we evaluated the effects of CPX in glucose homeostasis in WT diabetic mice. First asked is if CPX treatment induces p21 levels in the pancreas. To that end, mice received CPX orally at 0-25 mg/kg daily for 5 days and the levels of p21 were assessed. CPX administration from as low as 5 mg/kg effectively stimulated the expression of p21 in the pancreas of WT mice (Fig. 3a) . Subsequently, we explored the consequences of daily CPX at 25 mg/kg administration in glucose homeostasis of WT mice that became diabetic by receiving HFD combined with sucrose at 10 % in their drinking water. This experimental treatment started about 50 days after initiation of the diabetes-inducing diet, when fasting glucose levels were about 185 mg/dl. We used the higher dosage despite the efficient p21 stimulation at lower dosages on the basis of earlier results on the beneficial CPX administration at 25 mg/ml [39] . As shown in Fig. 3b , CPX at 25 mg/kg daily effectively improved glucose homeostasis causing reduction of blood glucose levels. Noteworthy, CPX administration in a diabetic mouse with glucose level at about 180 mg/dl was also effecting in stimulating p21, albeit at higher concentrations (Fig. 3a) . Glucose tolerance (Fig. 3c ) and insulin sensitivity (Fig. 3d) tests suggested that CPX did not affect drammatically the kinetics of plasma glucose in the diabetic mice, implying that its effects were not primarily in glucose metabolism. Ferritin levels were elevated in the sera of the diabetic mice and decreased significantly (P < 0.05) following CPX treatment (Fig. 3e) . The effects of CPX in glucose homeostasis were limited to the diabetic mice because glucose levels in WT non-diabetic mice were not affected by CPX administration (Fig. 4) . Histological analysis of pancreata from mice treated with CPX suggested that total islet numbers increased significantly only in the diabetic but not in the non-diabetic mice (Fig. 5) . It is noted that areas in the exocrine pancreas with cells exhibiting intense eosinophilic granular cytoplasm were detected in the CPX-treated groups which is consistent with increased activity.
Effects of CPX in insulin release and glucose-induced ER stress in islets
In order to understand better how CPX operates in β cells, we tested if it affects the efficiency by which insulin is produced following glucose stimulation. As shown in Fig. 6a , CPX suppressed the release of insulin. In view of the antidiabetic activity of CPX in vivo, the inhibition of insulin release appears contradictory. Thus, we hypothesized that reduced insulin secretion may be linked to reduced ER stress and blunted UPR, which in turn could explain in the long run the increased survival and functionality of the animals that received CPX. To test this hypothesis, we exposed islets to CPX (20 μμ) and high glucose (25 mμ) for 24 h and tested the levels of chaperones BiP, GRP94, and CHOP that reflect the intensity of the UPR. As shown in Fig. 6b , CPX alleviated the levels of BiP, GRP94, and CHOP in the WT islets, suggesting that the execution of the UPR was compromised. In line with these observations and consistently with the reduced insulin levels in the media (Fig. 6a) , the levels of insulin in the β islets were also suppressed (Fig. 6b) . In line with these findings is also the inhibitory activity of CPX in insulin release triggered by KCl that operates by promoting membrane depolarization (Fig. 6a) .
Effects of CPX in insulin release, ER stress, and ROS production induced by iron citrate
While modulation of insulin release by CPX constitutes a challenging mechanism by which CPX may affect ER stress, how CPX regulates insulin expression remains obscure. Being an iron chelator, it is conceivable that CPX modulates insulin production by adjusting the levels of bioavailable iron in the islets. To test this hypothesis, we exposed islets to increasing amounts of iron citrate for 24 h, alone or combined with CPX for 24 h, and recorded the levels of chaperones BiP, GRP94, and CHOP, as well as of insulin. As shown in Fig. 6a , increasing amounts of iron citrate triggered insulin production and induced the expression of ER stress markers BiP, GRP94, and CHOP. Concomitant exposure though, of islets with CPX, compromised the effects of iron citrate on insulin production and ER stress induction (Fig. 7a) . In addition to ER stress, CPX was also a potent inhibitor of ROS that was produced by the culture of islets to iron citrate and glucose at high or moderate concentrations (Fig. 7b) .
Discussion
Promotion of β cell survival emerges as an attractive target for the long-term management of diabetic patients. Recent results of our laboratory suggested that p21 protects mice from diet and streptozotocin (STZ)-induced diabetes by mechanisms involving a shift of the UPR from its pro-apoptotic to its adaptive function [14] [15] [16] . In line with these findings, genetic activation of p21 in β cells of transgenic mice protected them from STZ-induced pancreatic dysfunction [37] while pharmacological, p53-dependent activation of p21 by nutlin produced antidiabetic activity [16, 30] . In the present study, we confirmed the protective role of p21 in islets against glucotoxicity (Fig. 1 ) and evaluated the antidiabetic activity of CPX, a recently described activator of p21 expression [12] . Administration of CPX, an iron chelator that stimulates p21 by p53-independent mechanisms [39] , was strongly antidiabetic in mice at which diabetes was induced by HFD and sucrose-sweetened water (Fig. 3) . At least in part, this was due to the protection of islets from glucotoxicity (Fig. 2) . The ability of CPX to inhibit the production of high or moderate glucose-stimulated ROS production [38] may account for its protective effects in islets (Fig. 7b) .
The fact though that only in diabetic but not in nondiabetic controls serum glucose levels decreased by the CPX prompted us to explore if the antidiabetic activity of CPX is also related to metabolic effects associated with the stress induced by glucotoxicity. Indeed, assessment of insulin release in islets treated with CPX showed strong inhibition of insulin secretion triggered by high glucose (Fig. 6a) . Considering the antidiabetic action of CPX in mice, this inhibition of insulin secretion was rather unexpected. It is conceivable that CPX, besides its effects in islets, may also affect peripheral tissues in terms of insulin sensitivity in insulin-dependent organs, by modulating levels and activity of GLUT transporters, insulin receptor and signaling pathways, and gluconeogenesis. An additional possibility could be that by inhibiting the production of insulin, the β cells are less prone to develop ER stress which may compromise pancreatic function (Fig. 7) . To that end, an intriguing possibility is that CPX, by inhibiting insulin release, reduces ER stress in pancreatic islets which in turn improves long-term survival and function. Consistently with this notion, adequate regulation of glucose homeostasis may be attained by submaximal levels of insulin secretion, which, however, would not exhaust islets that could survive and function normally for more prolonged time periods. This concept raises the possibility that besides modulating the outcome of UPR (efficiency of ER stress-associated death), CPX also regulates the efficiency of UPR induction. This notion was also implied before [15] by our earlier observations that nutlin-3a, another stimulator of p21 expression, alleviates ER stress that is induced by high glucose. In addition, we have also reported that p53 ablation intensifies the UPR in mice inducing certain ER stress-associated pathologies in hepatocytes [4] . Indeed, assessment of the levels of the ER stress markers BiP, GRP94, and CHOP, in islets cultured in high glucose-containing media, showed that CPX reduced the intensity of the UPR (Fig. 6 ). Whether this effect of CPX is limited to islets under glucotoxic conditions or CPX operates, directly or indirectly, as a chaperone that assists protein folding, thus decreasing the risk of UPR, remains to be determined. It is noted though that CPX blocked the release of insulin that was triggered by KCl. The latter induces insulin release, by causing membrane depolarization through closing K ATP channels, causing elevation of cytosolic free Ca 2+ concentration [7, 20, 23, 24] . Thus, CPX, at least in part, may interfere with Ca 2+ homeostasis and membrane polarization, which in turn implies a wider role of CPX in the regulation of UPR and islets' function, beyond regulation of glucotoxicity. A moderate suppression in the levels of intracellular insulin was also recorded; however, it was less pronounced as compared to that recorded for the insulin released in the media (Fig. 5) . The fact that CPX only modestly suppressed insulin expression in the cells, but potently inhibited its release, suggests that this stimulator of p21 expression interferes mostly with insulin secretion than production. during CPX treatment and also that ER stress was not induced, but rather suppressed, imply that CPX operates upstream of insulin secretion, reducing the islets' sensitivity to glucose. To that end, in mice, during diet-induced diabetes, β cells retained their functionality and glucose homeostasis was attained despite that insulin production was compromised. It is noted that the rapid response to CPX treatment in vivo may imply additional levels at which CPX interferes with glucose homeostasis, beyond the promotion of islets' survival during glucose-induced stress of the ER. How CPX regulates insulin secretion remains vague. In view of its function as an iron chelator, and considering the relationship between iron and diabetes, CPX may reduce the cells' iron load, thus reducing the risk for diabetes onset [9, 32, 33] . Studies in both humans and experimental animals show association between the levels of ferritin and diabetes onset [31, 33] . In the present study, increased levels of ferritin were found in the sera of the diabetic mice while CPX treatment significantly reduced it (Fig. 3e) . Noteworthy, iron chelation with deferoxamine or deferasirox was also shown to be beneficial for diabetes management by a mechanism that depends on HIF-1α [3] . In this study, exposure of islets to iron citrate caused some induction in the expression of insulin, confirming and extending earlier observations on the stimulatory activity of iron to insulin [5] . This effect was dose dependent and was associated with the induction of ER stress-associated markers, especially at the higher doses of iron citrate (Fig. 6a) . Importantly, CPX that binds and titrates out iron alleviated the consequences of iron citrate in insulin production and reduced the intensity of ER stress (Fig. 7a) . In addition to ER stress, CPX also alleviated the production of ROS that was stimulated by iron citrate-in addition to high glucose (Fig. 7b) -further complicating the mechanism(s) contributing to the beneficial activity of CPX in islets' function and survival. Indeed, the ability of CPX to scavenge directly hydroxyl radicals has been demonstrated [28] . Noteworthy, CPX alleviated ROS production produced by excessive amounts of glucose, at 17 and 25 mM, and iron citrate, further confirming its function as a modulator of stress responses during stress. This ROS scavenging activity of CPX may also be relevant to the recorded inhibition of insulin secretion since previously described results suggest the stimulatory role of ROS in insulin production [22, 27] . In addition, the beneficial effects of antioxidants in islets' function have also been demonstrated [6, 13] .
It is noted that while our present and earlier findings are consistent with the pro-survival role of p21 during ER stress in β cells, a recent study demonstrated in INS-1-derived 832/13 cells and rat islets exogenous expression of p21 inducing apoptosis [8] . It is conceivable that during prolonged cell cycle arrest induced especially by the forced expression p21, cells and islets undergo untreated. b Expression of insulin, CHOP, GRP94, and BiP in WT islets treated with high glucose alone or in combination with CPX (in KRB). Actin levels were assessed as loading control. High glucose experiment was performed in triplicate. All values are expressed as average ±SD apoptosis without the latter reflecting a direct causative effect of p21 activation. Indeed, a series of studies in diverge cellular systems demonstrated that p21 is prosurvival following different forms of stress including ER stress [19] and is capable of activating various mitogenic ques such as those trigerred by CDK8 [2, 25, 26, 36] . Finally, our earlier studies showed that p21s undergo stimulation followed by suppression during intense/ prolonged ER stress [14, 15] . The overall role of p21 in β cells is rather complex, and the actual fate of cells represents the collective outcome of the combined intensity of the pro-apoptotic (ER stress) and the pro-survival signals (p21).
Although no evidence of toxicity was detected in the CPX-treated groups, such as loss of body weight, signs of cachexia, or gross morphological alterations during necropsy, it is formally possible that at least partially, the effects of CPX in vivo were due to kidney toxicity and increased excretion of glucose in the urine. However, the in vitro results on pancreatic islets strongly support that at least partially, these effects are due to the promotion of islets' survival during glucotoxicity.
Collectively, our findings suggest that CPX is beneficial for diabetes. It is likely that this is attained by converging mechanisms related both to the modulation of the p21-dependent sensitivity of β cells to ER stress-related Ins Fig. 7 Iron citrate elevates ER stress markers, whereas ciclopirox restores ER stress homeostasis. a The effects of iron citrate and ciclopirox at the indicated concentrations in insulin, BiP, GRP94, and CHOP levels in islets cultured at 5.5 mM glucose. Actin levels were assessed as loading control. The high glucose experiment was performed in triplicate. b Effect of CPX at 20 μM (in KRB) for 24 h in ROS production (in arbitrary units, AU) that was triggered by high (25 mM) or moderate (17 mM) glucose (Glu) or iron citrate (Fe) (in 5.5 mM glucose). TBHP was used as positive control for ROS production. *P < 0.05, Student's t test. All values are expressed as average ±SD apoptosis and by the regulation of the induction of UPR as such, through inhibition of insulin release that constitutes a major stimulator of ER stress in β cells. These activities involve mechanisms that appear to be both β cell specific, such as regulation of insulin production, and mechanisms that may operate in additional cell types as well such as the alleviation of ROS production (Fig. 8) . Thus, the beneficial activity of CPX may be not limited only to the management of diabetes but also to other ER stress-associated diseases. 
